Edition:
United Kingdom

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

1.43USD
23 Aug 2019
Change (% chg)

$-0.01 (-0.69%)
Prev Close
$1.44
Open
$1.44
Day's High
$1.54
Day's Low
$1.40
Volume
74,463
Avg. Vol
77,881
52-wk High
$14.52
52-wk Low
$1.40

About

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR,... (more)

Overall

Beta: --
Market Cap(Mil.): $763.12
Shares Outstanding(Mil.): 93.52
Dividend: --
Yield (%): --

Financials

  ADAP.OQ Industry Sector
P/E (TTM): -- 69.38 32.67
EPS (TTM): -1.00 -- --
ROI: -32.06 8.95 14.48
ROE: -35.60 10.09 15.78
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates